ヒクマ製薬の株価は製造の遅れによる低成長予測により2025年11月6日に14.1%下落した. Hikma Pharmaceuticals shares fell 14.1% on Nov. 6, 2025, on lower growth forecasts due to manufacturing delays.

ヒクマ製薬の株価は2025年11月6日木曜日,14%減でGBX 1,522に落下し,中期見通し修正に伴い,取引量が平均より7,989%高い166百万株に急上昇した. Hikma Pharmaceuticals shares dropped 14.1% to GBX 1,522 on Thursday, November 6, 2025, amid a surge in trading volume to 166 million shares—7,989% above average—following a revised medium-term outlook. 同社は,ベドフォード製造施設の遅滞により,同社の成長予測を低下させ,2027年後半まで全事業を推し進めた. The company lowered its growth forecasts for its injectables division due to delays at its Bedford manufacturing facility, pushing full operations to late 2027. 分析者は,下落にもかかわらず,GBX 2,615の"買い"のコンセンサス評価と目標価格を維持し,Hikmaは2025年全年の予測を再確認した. Despite the decline, analysts maintain a "Buy" consensus rating and a target price of GBX 2,615, while Hikma reaffirmed its full-year 2025 guidance. 株式の価格は,50日と200日との動向の平均値より下がったままであり,その勢いは下がったことを示唆している. The stock’s price remains below its 50-day and 200-day moving averages, suggesting downward momentum.